Jane Street
SYRS

Jane Street’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Jane Street’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,260
Closed -$178K – 10908
2021
Q2 		$178K Buy
3,260
+180
+6% +$10.7K ﹤0.01% 8913
2021
Q1 		$230K Buy
+3,080
New +$320K ﹤0.01% 8084

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Jane Street's SYRS Position: Q1 2025 in Review

Jane Street sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 52,920 shares — an estimated $12.2K sold.

Jane Street first reported a position in SYRS in Q4 2020 and held it in 12 quarters. The position peaked at $923K in Q1 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Jane Street reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Jane Street sold 52,920 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $12.2K.
  • Jane Street first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • Jane Street's Syros Pharmaceuticals, Inc. Common Stock position peaked at $923K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.